Barclays raised the firm’s price target on Boston Scientific to $78 from $70 and keeps an Overweight rating on the shares. The company reported “unusually strong” Q1 organic growth of 13% and lifted its full-year growth outlook, boosting investor confidence in the ability of its portfolio to deliver sustainable, broad-based growth, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Upcoming Deadline to Share in Boston Scientific Corporation (BSX) Class Action Settlement
- Boston Scientific price target raised to $73 from $63 at Deutsche Bank
- Boston Scientific price target raised to $83 from $70 at Stifel
- Boston Scientific sees FY24 adjusted EPS $2.29-$2.34, consensus $2.25
- Boston Scientific sees Q2 adjusted EPS 57c-59c, consensus 56c